Physician profile
Steven D Dolacky
NPI 1528384690
$6,972.02
in general payments reported to CMS, 2019-2025
33 companies · $730 in 2025
The $730 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,141 · 2020: $314 · 2021: $257 · 2022: $582 · 2023: $1,138 · 2024: $810 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,677.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,469.11 | 2019-2025 | 2nd Gen Centrimag Primary Console, Xience Skypoint, Ensite |
| Boston Scientific Corporation | $1,068.64 | 2019-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $767.57 | 2019-2025 | Lifevest |
| Amgen INC. | $441.30 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $230.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $197.77 | 2019-2020 | |
| Atricure, INC. | $193.33 | 2023-2024 | |
| Pfizer INC. | $172.01 | 2019-2024 | |
| Philips North America LLC | $152.20 | 2019-2022 | |
| Cardiva Medical, INC. | $148.14 | 2023-2025 | Savvywire, Ensoetm, Cardiva Vascade Mvp Vvcs 6-12f |
| Teleflex LLC | $126.57 | 2019-2025 | Guideliner, Turnpike, Vascband |
| Inspire Medical Systems, INC. | $115.36 | 2024-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $108.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $107.20 | 2019-2022 | |
| Abiomed | $89.12 | 2023 | Impella |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $85.40 | 2025 | Pascal |
| Heartflow, INC. | $67.75 | 2025 | |
| Sanofi-Aventis U.S. LLC | $65.39 | 2019-2023 | |
| Biosense Webster, INC. | $42.85 | 2019-2023 | Carto 3 |
| Gilead Sciences, INC. | $38.38 | 2019 | |
| Akcea Therapeutics, INC. | $36.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.34 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $27.85 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $25.48 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $24.83 | 2019-2020 | |
| Lundbeck LLC | $24.71 | 2019 | |
| Baxter Healthcare | $21.48 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $17.70 | 2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $17.69 | 2019 | |
| Genzyme Corporation | $15.71 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.64 | 2019 | |
| Irhythm Technologies, INC. | $12.88 | 2020 | |
| Alnylam Pharmaceuticals INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dolacky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.